Latest Articles
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis - Nature
Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis Nature
Published: Aug. 13, 2025, 2:22 p.m.
Link copied to clipboard!